CYXONE AB SK-75
Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, … Read more
CYXONE AB SK-75 (4CX) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CYXONE AB SK-75 (4CX) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CYXONE AB SK-75 - Net Assets Trend (None–None)
This chart illustrates how CYXONE AB SK-75's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CYXONE AB SK-75 (None–None)
The table below shows the annual net assets of CYXONE AB SK-75 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CYXONE AB SK-75's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CYXONE AB SK-75 Competitors by Market Cap
The table below lists competitors of CYXONE AB SK-75 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MEMSCAP (MSBA.SG)
STU:MSBA
|
$40.59K |
|
Urbana Corporation
PINK:URNAF
|
$40.60K |
|
AGROKULTURA
BE:9AA
|
$40.62K |
|
Terra Innovatum Global N.V. Ordinary shares
NASDAQ:NKLR
|
$40.62K |
|
LOGG3F
SA:LOGG3F
|
$40.42K |
|
G-Tec Jainx Education Limited
NSE:GTECJAINX
|
$40.32K |
|
ROYAL MAIL
BE:RYE
|
$40.32K |
|
Pensana Rare Earths Plc
LSE:PRE
|
$40.32K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CYXONE AB SK-75's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CYXONE AB SK-75's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CYXONE AB SK-75 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CYXONE AB SK-75's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CYXONE AB SK-75 (4CX) | €- | N/A | N/A | $40.46K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |